These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 38275966)
1. Antivirals for Broader Coverage against Human Coronaviruses. Outteridge M; Nunn CM; Devine K; Patel B; McLean GR Viruses; 2024 Jan; 16(1):. PubMed ID: 38275966 [TBL] [Abstract][Full Text] [Related]
2. Current Strategies of Antiviral Drug Discovery for COVID-19. Mei M; Tan X Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887 [TBL] [Abstract][Full Text] [Related]
3. Properties of Coronavirus and SARS-CoV-2. Malik YA Malays J Pathol; 2020 Apr; 42(1):3-11. PubMed ID: 32342926 [TBL] [Abstract][Full Text] [Related]
4. Investigating theobromine as a potential anti-human coronaviral agent. Li J; Wang Y; Rajpoot S; Lavrijsen M; Pan Q; Li P; Baig MS Microbiol Immunol; 2023 Sep; 67(9):404-412. PubMed ID: 37415325 [TBL] [Abstract][Full Text] [Related]
5. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. Bchetnia M; Girard C; Duchaine C; Laprise C J Infect Public Health; 2020 Nov; 13(11):1601-1610. PubMed ID: 32778421 [TBL] [Abstract][Full Text] [Related]
6. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. Zimmermann P; Curtis N Pediatr Infect Dis J; 2020 May; 39(5):355-368. PubMed ID: 32310621 [TBL] [Abstract][Full Text] [Related]
7. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2. Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596 [TBL] [Abstract][Full Text] [Related]
8. A low-background, fluorescent assay to evaluate inhibitors of diverse viral proteases. Leonard RA; Rao VN; Bartlett A; Froggatt HM; Luftig MA; Heaton BE; Heaton NS J Virol; 2023 Aug; 97(8):e0059723. PubMed ID: 37578235 [TBL] [Abstract][Full Text] [Related]
9. Genetic Surveillance of SARS-CoV-2 M Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764 [TBL] [Abstract][Full Text] [Related]
10. Emergence and Re-emergence of Human Coronaviruses: Spike Protein as the Potential Molecular Switch and Pharmaceutical Target. Ahmad F; Kamal MA; Tekwani BL Curr Pharm Des; 2021; 27(33):3566-3576. PubMed ID: 33327904 [TBL] [Abstract][Full Text] [Related]
11. Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge. Wang G; Verma AK; Guan X; Bu F; Odle AE; Li F; Liu B; Perlman S; Du L J Virol; 2024 Sep; 98(9):e0037624. PubMed ID: 39189731 [TBL] [Abstract][Full Text] [Related]
12. Lessons learnt from broad-spectrum coronavirus antiviral drug discovery. Bolinger AA; Li J; Xie X; Li H; Zhou J Expert Opin Drug Discov; 2024 Sep; 19(9):1023-1041. PubMed ID: 39078037 [TBL] [Abstract][Full Text] [Related]
13. Ocular tropism of coronavirus (CoVs): a comparison of the interaction between the animal-to-human transmitted coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS-CoV, CoV-229E, NL63, OC43, HKU1) and the eye. Al-Sharif E; Strianese D; AlMadhi NH; D'Aponte A; dell'Omo R; Di Benedetto R; Costagliola C Int Ophthalmol; 2021 Jan; 41(1):349-362. PubMed ID: 32880786 [TBL] [Abstract][Full Text] [Related]
14. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205 [TBL] [Abstract][Full Text] [Related]
15. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection. Krishna G; Pillai VS; Veettil MV Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174 [TBL] [Abstract][Full Text] [Related]
16. Repurposing dyphylline as a pan-coronavirus antiviral therapy. Wang Y; Rajpoot S; Li P; Lavrijsen M; Ma Z; Hirani N; Saqib U; Pan Q; Baig MS Future Med Chem; 2022 May; 14(10):685-699. PubMed ID: 35387498 [No Abstract] [Full Text] [Related]
17. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. Kandeel M; Ibrahim A; Fayez M; Al-Nazawi M J Med Virol; 2020 Jun; 92(6):660-666. PubMed ID: 32159237 [TBL] [Abstract][Full Text] [Related]
18. Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor. Weil T; Lawrenz J; Seidel A; Münch J; Müller JA Antiviral Res; 2022 Jul; 203():105343. PubMed ID: 35598779 [TBL] [Abstract][Full Text] [Related]
19. The Nucleocapsid Proteins of SARS-CoV-2 and Its Close Relative Bat Coronavirus RaTG13 Are Capable of Inhibiting PKR- and RNase L-Mediated Antiviral Pathways. LeBlanc K; Lynch J; Layne C; Vendramelli R; Sloan A; Tailor N; Deschambault Y; Zhang F; Kobasa D; Safronetz D; Xiang Y; Cao J Microbiol Spectr; 2023 Jun; 11(3):e0099423. PubMed ID: 37154717 [TBL] [Abstract][Full Text] [Related]
20. Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography. Wang J; Li D; Zhou Q; Wiltse A; Zand MS Front Immunol; 2021; 12():696370. PubMed ID: 34386006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]